Immuneering shared new AACR pancreatic cancer data showing atebimetinib may improve survival by reducing tumor volume while preserving body mass. The early findings add momentum to its Phase 3 MAPKeeper 301 study.
published
Immuneering shared new AACR pancreatic cancer data showing atebimetinib may improve survival by reducing tumor volume while preserving body mass. The early findings add momentum to its Phase 3 MAPKeeper 301 study.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.